The Delhi government has banned the sale, purchase and distribution of Coldrif cough syrup after it was declared "not of standard quality", an official order said.
According to the order issued on Friday, Coldrif Syrup (Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate Syrup), manufactured in May 2025 by Sresan Pharmaceutical Manufacturer, Tamil Nadu, was found to be adulterated with Diethylene Glycol (46.28 per cent w/v), a toxic chemical known to be harmful to human health.
All stakeholders are directed to immediately stop selling, purchasing, or distributing the said batch of the syrup. The general public has also been advised not to use the product, given its potential health risks, the order said.
The assistance of all stakeholders is sought for the strict implementation and wide dissemination of the public advisory, which has been issued in public interest, it said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)